ストックスクリーナーアプリを入手
58.07
2.67%
-1.59
アフターアワーズ：
58.20
0.13
+0.22%
Moderna Inc (MRNA) 最新ニュース
Biotech experts want FDA drug reviews based on science, not politics - marketscreener.com
Himension Capital Singapore PTE. LTD. Cuts Position in Moderna, Inc. $MRNA - MarketBeat
Moderna Rabies Vaccine Candidate by Moderna Inc.mRNA approach in early trials - Ad-hoc-news.de
Bank of New York Mellon Corp Reduces Position in Moderna, Inc. $MRNA - MarketBeat
California Public Employees Retirement System Purchases 149,192 Shares of Moderna, Inc. $MRNA - MarketBeat
Is Moderna (MRNA) Fully Valued As Board Changes And Earnings Near? - Yahoo! Finance Canada
Moderna (MRNA) Appoints Michael McDonnell To Board As Committee Roles Shift - Yahoo Finance UK
The mRESV by Moderna. An mRNA RSV vaccine candidate for older adults - Ad-hoc-news.de
IXJ vs. RSPH: Which Healthcare ETF Is the Better Buy? - The Motley Fool
Moderna stock stabilizes as oncology pipeline and vaccine revenue reshape growth outlook - Ad-hoc-news.de
MRNA Maintained and Target Raised by Goldman Sachs -- Now $67.00 - GuruFocus
Moderna stock outlook: doubled YTD but Wall Street says the easy money is made - Investing.com
Moderna, Inc. $MRNA Stock Holdings Increased by Fifth Third Bancorp - MarketBeat
Moderna Hits CureVac With Countersuit In COVID Vax Fight - Law360
Moderna Is Up 109% in 2026. Jim Cramer Just Called It 'Finally Investable Again.' Is the Stock a No-Brainer Buy on Its Recent Pullback? - Yahoo Finance
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo! Finance Canada
Moderna, Inc.'s Stock Price Drops to $59.49, a Decline of 3.77%, Investors Eye Market Performance Closely - Smartkarma
Moderna says CureVac broke agreement by suing over COVID vaccine patents - Reuters
Moderna stock steadies as RSV and COVID vaccine revenues reshape outlook - Ad-hoc-news.de
Moderna counters CureVac patent lawsuit over Covid-19 vaccines By Investing.com - Investing.com Canada
Goldman Sachs Adjusts Moderna Price Target to $67 From $49, Maintains Neutral Rating - marketscreener.com
Wolfe Research raises Moderna stock price target to $25 on updates - Investing.com
D.A. Davidson & CO. Decreases Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna | History, Innovation, Challenges, & Facts | Britannica Money - Encyclopedia Britannica
Moderna stock edges higher as Spikevax sales stabilize and pipeline spending stays elevated - ad-hoc-news.de
The mRNA-1345 RSV vaccine candidateModerna Inc. bets on older adults - Ad-hoc-news.de
US Seeks Toss Of Arbutus Patent Suit Over Moderna Vaccine - Law360
Moderna stock trades lower as COVID vaccine demand weighs on 2026 outlook - ad-hoc-news.de
Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Moderna stock trades steadily as mRNA pipeline and COVID revenues shape outlook - ad-hoc-news.de
Fed. Circ. Asked Not To Shift Moderna Vax Patent Case To Gov't - Law360
Form 4 Moderna Inc For: 16 July By Investing.com - Investing.com Nigeria
Moderna, Inc.’s Stock Price Plummets to $63.15, Marking a Significant 7.51% Decline - Smartkarma
Moderna president Stephen Hoge sells $3.6m in stock - Investing.com
Moderna, Inc. (MRNA) president exercises options and sells 53,336 shares under 10b5-1 plan - Stock Titan
Lobbying Update: $290,000 of MODERNA INC. lobbying was just disclosed - Quiver Quantitative
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection? - Stocktwits
The mRESVAI trial for RSV vaccine by Moderna Inc.early data underline a strategic bet on respirat - ad-hoc-news.de
Moderna advances its cancer therapy assessment, but the stock slides - marketscreener.com
ETFs Investing in Moderna, Inc. Stocks - TradingView
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors - Investing News Network
(MRNA) Risk Channels and Responsive Allocation - Stock Traders Daily
Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech -- Update - marketscreener.com
Moderna (MRNA) Begins Trial for New Cancer Immunotherapy - GuruFocus
Arbutus (ABUS) Secures $178 Million Settlement with Moderna - GuruFocus
Moderna doses first patient in cancer therapy trial - Investing.com
Arbutus Biopharma Files International Patent Lawsuits Against Pfizer and BioNTech, Announces Moderna Settlement Payment and Plans for Capital Return - Quiver Quantitative
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders - The Manila Times
Arbutus Biopharma (Nasdaq: ABUS) receives $178M from Moderna, eyes $230M buyback - Stock Titan
Sanofi sues Pfizer, Moderna over COVID shot technology - Reuters
Sanofi Sues Moderna, Pfizer for Vaccine-Tech Patent Royalties - Bloomberg Law News
Form 144 Moderna For: 15 July By Investing.com - Investing.com Canada
Moderna (NASDAQ: MRNA) holder Stephen Hoge plans 53,336-share sale - Stock Titan
Moderna's Ambitious Pivot: Why Its Science Day Vision Outruns Today's Valuation - Kavout | AI
Sanofi Says Pfizer, Moderna COVID Jabs Infringe MRNA Tech - Law360
Gov't Shouldn't Face Vax Suit Targeting Moderna, Group Says - Law360
Moderna set for uneventful Q2 report ahead of key data readouts, says Jefferies - Yahoo Finance
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance Singapore
Moderna, Takeda and Capricor on the verge of notching big drug approvals - Pharma Voice
The mRESV-101 vaccine candidateModerna Inc. bets on RSV protection in older adults - Ad Hoc News
Jefferies Adjusts Price Target on Moderna to $60 From $53, Maintains Hold Rating - marketscreener.com
What It Means To Hold Moderna Stock In A Crash - Yahoo Finance
1.36%
0.51%
大文字化:
|
ボリューム (24 時間):